CareYaya’s MedaCareLLM AI Glasses Support Dementia Patients
CareYaya Health Technologies, recognised as one of LinkedIn's Top 50 Startups, has unveiled MedaCareLLM, an innovative AI-powered large language model designed to support individuals living with dementia and Alzheimer's disease.
This technology integrates seamlessly with smart glasses, an increasingly popular tool for supporting those with mobility or memory issues.
As one of the fastest-growing health tech startups in the United States, CareYaya has garnered support from prestigious institutions including the Johns Hopkins University Artificial Intelligence & Technology Collaboratory, AARP's AgeTech Collaborative and the National Institutes of Health.
The company's mission centres on developing technologies to enhance the lives of older adults and those affected by dementia, while also operating a platform that connects caregivers, particularly healthcare students, with those in need.
AI-driven smart glasses transforming care for dementia patients
MedaCareLLM is a key component of CareYaya's OpenMind Project, an initiative aimed at creating a comprehensive multimodal dataset of cognitive and neurological information from older adults.
By collecting video, audio and visual gaze data through smart glasses, CareYaya is developing sophisticated AI models capable of:
- Recognising and tracking disease progression
- Monitoring medication adherence
- Tracking daily dietary patterns
- Assisting with various daily tasks
The smart glasses equipped with MedaCareLLM utilise advanced AI technology, incorporating video data, facial recognition and object recognition to provide real-time, personalised assistance to users.
For Neal K. Shah, CEO and Co-Founder, CareYaya Health Technologies, the future of dementia care has taken a monumental leap forward.
“After two years of pioneering development with leading experts in neuroscience and AI, we are delighted to unveil MedaCareLLM—an ‘AI that prompts you.’ This groundbreaking technology, delivered through smart glasses, provides real-time cues for patients, from recognising loved ones to managing medications, ushering in a new era of dementia care,” said Neal. “CareYaya is driven by tackling the disparity in dementia research. Black seniors are twice as likely to develop Alzheimer’s but are severely underrepresented in studies. MedaCareLLM, powered by our inclusive OpenMind dataset, is changing that. Additionally, families using MedaCareLLM tell us their loved ones feel more independent, confident, and, most importantly—more like themselves."
Eli Lilly’s donanemab receives MHRA approval for early Alzheimer's treatment
Pharmaceutical manufacturer Eli Lilly is also making progress against dementia. The company recently announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for donanemab, an injection for intravenous infusion which treats mild cognitive impairment and mild dementia.
Donanemab is the only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed.
"People around the world want and deserve access to treatment options for this disease. This approval is another significant step to ensure patients with Alzheimer's disease can receive treatment with this new class of amyloid targeting therapies, which could give them more time in the early symptomatic stage of the disease to do what matters most to them," said Ilya Yuffa, Executive Vice President and President of Lilly International, Eli Lilly and Company.
Donanemab has demonstrated meaningful results for people with early symptomatic Alzheimer's disease, through slowing cognitive and functional decline.
"We can improve the standard of care for people living with Alzheimer's disease. Despite years of medical research, until recently, there has been little progress in treatment options for this disease,” shared Professor Cath Mummery, Consultant Neurologist at University College London Hospitals NHS Foundation Trust and Chair of the NIHR Dementia Translational Research Collaboration. “The authorisation of donanemab for eligible adults is welcome news.”
Make sure you check out the latest industry news and insights at Healthcare Digital and also sign up to our global conference series - Healthcare LIVE 2025
Healthcare Digital is a BizClik brand
